UK Markets closed

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7900+0.1300 (+4.89%)
At close: 04:00PM EDT
2.7900 0.00 (0.00%)
After hours: 05:00PM EDT

Cyteir Therapeutics, Inc.

128 Spring Street
Building A Suite 510
Lexington, MA 02421
United States
857 285 4140
https://cyteir.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees40

Key executives

NameTitlePayExercisedYear born
Mr. Joseph S. ZakrzewskiIndependent Investor & Chairman60.05kN/A1962
Dr. Markus F. Renschler M.D.Pres, CEO & Director630kN/A1961
Mr. Timothy RombergerIndependent DirectorN/AN/A1973
Dr. Paul Secrist Ph.D.Chief Scientific Officer265.23kN/A1966
Mr. Andrew W. GengosChief Bus. Officer436.51kN/A1964
Dr. Kevin Mills Ph.D.Co-FounderN/AN/AN/A
Mr. David G. GaieroVP of Fin.N/AN/A1979
Ms. Lisa A. HayesVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Adam M. Veness Esq.Gen. CounselN/AN/A1986
Ms. Gale CohenVP of HRN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Corporate governance

Cyteir Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.